Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › R&D spending
NewAmsterdam Pharma Co N.V. (NAMS) R&D spending by quarter
NewAmsterdam Pharma Co N.V.'s R&D spending was $39.4M in Q3 2026 (third quarter 2026), -6% from Q2 2026. Over the last 7 quarters it ranged from $27.5M (Q2 2025) to $44.8M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $39.4M | -6% | +27% |
| Q2 2026 | $41.7M | +10% | +51% |
| Q1 2026 | $38.0M | -2% | -15% |
| Q4 2025 | $38.6M | +25% | — |
| Q3 2025 | $31.0M | +13% | — |
| Q2 2025 | $27.5M | -39% | — |
| Q1 2025 | $44.8M | — | — |
Q3 2026 at a glance
NewAmsterdam Pharma Co N.V., Q3 2026: revenue $19.2M (55× year over year), operating margin -230.6%, net loss $17.4M, operating cash flow −$39.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is NewAmsterdam Pharma Co N.V.'s R&D spending?
NewAmsterdam Pharma Co N.V.'s R&D spending was $39.4M in Q3 2026 (third quarter 2026), -6% from Q2 2026.
How has NewAmsterdam Pharma Co N.V.'s R&D spending changed?
Over the last 7 quarters it ranged from $27.5M (Q2 2025) to $44.8M (Q1 2025).
Q3 2026 results → · How NewAmsterdam Pharma Co N.V. makes money →